Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a cell therapy it’s developing called FT500 to treat advanced solid tumors. (본문 전체 12/2/2018 2:07 AM)